Latest Regulatory Filings News

Vonex Limited has taken a key step in its acquisition by Maxo Telecommunications, lodging a draft Scheme Booklet with ASIC that includes an independent expert’s report. This move brings the proposed takeover closer to shareholder approval and regulatory clearance.

Imagion Biosystems has made significant progress towards filing an Investigational New Drug application for its MagSense® HER2 breast cancer imaging agent, receiving encouraging feedback from the FDA and preparing for a Phase 2 clinical trial.

Domain Holdings Australia has received a draft class ruling from the ATO that aligns with its previously disclosed tax positions for the upcoming CoStar acquisition scheme. The final ruling, expected post-implementation, will provide definitive tax clarity for shareholders.

Macarthur Minerals Limited’s MIOOB securities have been suspended from trading due to non-compliance with ASX listing rules, raising questions about the company’s regulatory standing.

AVJennings Limited shares will halt trading following court approval of a takeover scheme by PM Nominees C Pty Ltd, marking a pivotal shift for the property developer.

I Synergy Group Limited has disclosed a non-binding Memorandum of Understanding following a sharp rise in its share price and trading volume, addressing ASX concerns over market transparency.

D3 Energy has achieved a significant milestone with its maiden certified methane and helium reserves at ER315 in South Africa, enabling an early submission of its Production Right application. The reserves cover a small portion of the acreage but signal substantial upside potential.

Tetratherix Limited has marked a pivotal quarter with a $25 million ASX listing, an exclusive licensing agreement with Bio Optix for ophthalmic devices, and progress on FDA regulatory submissions for its prostate spacer product.

Firebrick Pharma has published positive Phase 3 clinical trial results for its Nasodine nasal spray, showing efficacy against the common cold, while reporting encouraging sales growth in Singapore and the US. However, a recent capital raise fell well short of targets, casting uncertainty over its expansion plans.

Strickland Metals plans a capital return by distributing 1.2 billion Gateway Convertible Preference Shares to its shareholders, significantly reducing its stake and reshaping ownership. The move awaits shareholder approval and hinges on conditions tied to an asset sale agreement.

Imagion Biosystems has received encouraging feedback from the FDA on its MagSense HER2 breast cancer imaging program, clearing the path for a Phase 2 clinical trial and fast-tracking manufacturing.

INOVIQ Limited reports strong clinical validation for its EXO-OC ovarian cancer screening test and promising preclinical results for CAR-exosome therapeutics targeting aggressive cancers.